^®BAVENCIO^®(Avelumab for injection)

Solution for Intravenous Infusion

• 20 mg/mL

Professed Standard Therapeutic Classification: Antineoplastic

BAVENCIO has been issued marketing authorization with conditions for the treatment of: 

• Patients with locally advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy. 

These indications are pending the results of studies to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for BAVENCIO please refer to Health Canada’s Notice of Compliance with conditions - drug products web site: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions/index-eng.php. 

BAVENCIO has been issued marketing authorization without conditions for: 

• Maintenance treatment of patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed following first-line platinum-based chemotherapy. 
• Treatment of adult patients with metastatic Merkel cell carcinoma (MCC).